UCB (OTCMKTS:UCBJF) Stock Rating Upgraded by Jefferies Financial Group

UCB (OTCMKTS:UCBJF) was upgraded by Jefferies Financial Group to a “buy” rating in a research report issued on Thursday, TipRanks reports. The brokerage presently has a $130.00 price objective on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 22.64% from the stock’s current price.

Other analysts also recently issued reports about the company. Deutsche Bank Aktiengesellschaft assumed coverage on UCB in a research report on Friday, July 23rd. They set a “buy” rating and a $105.39 target price on the stock. JPMorgan Chase & Co. upgraded UCB to a “buy” rating and set a $150.00 target price on the stock in a research report on Thursday, September 2nd. UBS Group upgraded UCB to a “buy” rating and set a $116.00 target price on the stock in a research report on Monday, August 23rd. Societe Generale assumed coverage on UCB in a research report on Friday, July 9th. They issued a “buy” rating and a $115.00 price objective on the stock. Finally, BNP Paribas upgraded UCB to a “buy” rating and set a $110.00 price objective on the stock in a research report on Monday, July 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, UCB has a consensus rating of “Buy” and an average target price of $121.07.

UCBJF opened at $106.00 on Thursday. The business’s fifty day moving average is $108.21 and its two-hundred day moving average is $101.17. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market cap of $20.04 billion, a price-to-earnings ratio of 17.32 and a beta of 0.60. UCB has a one year low of $93.00 and a one year high of $116.50.

UCB Company Profile

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

See Also: Is it better to buy a fund with a higher or lower NAV?

Analyst Recommendations for UCB (OTCMKTS:UCBJF)

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.